Last Friday, the Dana-Farber Cancer Institute in Boston hosted a symposium for patients diagnosed with Gastrointestinal Stromal Tumor (GIST) and their families. The all-day event, “Living with GIST”, was not only informative for GIST patients, but was also a celebration. The event marked the ten-year anniversary of finding a successful treatment for GIST.
GIST is a rare type of cancer that affects the body’s digestive tract and its nearby abdominal structures. Unlike the majority of cancers, which are carcinomas, GIST tumors are sarcomas and do not respond to chemotherapy or radiation therapy. As Dr. George Demetri explained to the audience, prior to the development of effective treatments, GIST tumors were surgically removed until it was no longer clinically effective to do so. The development of molecular targeted therapy, such as Imatinib (Gleevec) and Sunitinib (Sutent), changed the prognosis for GIST patients, bringing hope where there had been none.
Dr. Demetri and his colleagues shared the joy of the early days of the Imatinib clinical trials, when they saw the previously untreatable cancer tumors shrinking and stabilizing after short trials of drug therapy. The enthusiasm of Dr. Demetri and his colleagues, combined with the stories of hard work and barriers overcome, spoke to the amazing accomplishments of these medical professionals.